Guildford, UK, 4 December 2012: ReNeuron announces that it will be participating at the UK Stroke Association’s 7th UK Stroke Forum conference taking place in Harrogate on 4-6 December.

ReNeuron is delighted to be a sponsor of the conference again this year and will be hosting a satellite symposium on 5 December. At the symposium, Professor Keith Muir (SINAPSE Chair of Clinical Imaging & Consultant Neurologist, University of Glasgow) will give an update on progress with the PISCES clinical trial of ReNeuron’s ReN001 stem cell therapy for stroke disability. Professor Muir is the Principal Investigator for this Phase I study, currently taking place in Scotland at the Institute of Neurological Sciences, Southern General Hospital, Greater Glasgow and Clyde NHS Board.

ReNeuron will also present at the symposium. ReNeuron’s presentation will focus on the considerations for future clinical development of the ReN001 therapy and how the therapy could be targeted at particular patient sub-populations to ensure both maximum clinical benefit and cost-effectiveness based on UK healthcare system reimbursement principles.

Further information about the conference may be found at

No new material information will be disclosed at the symposium.


  1. ReNeuron                  +44 (0) 1483 302560
    Michael Hunt, Chief Executive Officer
    Dr John Sinden, Chief Scientific Officer
  2. Buchanan                   +44 (0) 20 7466 5000
    Mark Court, Fiona Henson, Sophie Cowles    

Cenkos Securities      +44 (0) 20 7397 8900
Stephen Keys, Adrian Hargrave (NOMAD and Broker)
Andy Roberts (Sales)

About ReNeuron
ReNeuron is a leading, clinical-stage stem cell business.  Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.  

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered “off-the-shelf” to any eligible patient without the need for additional immunosuppressive drug treatments.  ReNeuron’s lead candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. This therapy is currently in clinical development.  The Company is also developing stem cell therapies for other conditions such as critical limb ischaemia, a serious and common side-effect of diabetes, and blindness-causing diseases of the retina such as retinitis pigmentosa.

ReNeuron has also developed a range of stem cell lines for non-therapeutic applications – its ReNcell® products for use in academic and commercial research.  The Company’s ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Merck Millipore.

ReNeuron’s shares are traded on the London AIM market under the symbol RENE.L.  Further information on ReNeuron and its products can be found at